Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Astellas agrees €800m deal to buy Belgian biotech Ogeda

Will pay another €300m if fezolinetant meets clinical and regulatory targets

- PMLiVE

John LaMattina joins Frequency Therapeutics in advisory role

The ex-Pfizer R&D head will sit on its Scientific Advisory Board

Sam Agus takes up new role at Hansa Medical

Will focus on the firm’s lead kidney transplantation project IdeS

- PMLiVE

Makara Health launches compliance training division

Collaborates with Dr Nick Broughton on the new programme

- PMLiVE

Snapchat arrives at scientific meetings

And NICE becomes the first public health body to use the platform

- PMLiVE

Novartis gets lung cancer OK for Tafinlar/Mekinist combo

It can now be used to treat BRAF V600E-positive NSCLC patients in Europe

Verona Pharma strengthens senior management team

Richard Hennings joins as commercial director

- PMLiVE

Pfizer keeps nose ahead of rivals with new Ibrance approval

FDA licenses new indication for the breast cancer treatment

The Medicines Company strengthens board of directors

Paris Panayiotopoulos joins from ARIAD Pharmaceuticals

- PMLiVE

Connecting the dots

What happens ‘here’ impacts what happens ‘there’

- PMLiVE

Danish Medicines Agency urges caution on health app use

Says mobile applications on their own cannot make a diagnosis

- PMLiVE

Behaviour change needs a quantified approach

How pharmaceutical brands can use behaviour change to communicate their treatments to patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links